2023 Early Hearing Detection & Intervention Conference
March 5-7, 2023 • Cincinnati, OH
8/23/2022 | 1:35 PM - 2:00 PM | Identifying clinical criteria for an enhanced targeted approach to screening for congenital CMV infe | Governor General I
Identifying clinical criteria for an enhanced targeted approach to screening for congenital CMV infe
Background: While targeted screening for congenital CMV infection (cCMV) of infants who fail their newborn hearing screen is common practice, this strategy fails to identify many infants with non-specific signs of cCMV at birth. Methods: In this retrospective study of newborns tested for cCMV infection in Montreal between 2014 and 2018, we describe the incidence of infection according to indications for testing, and most common presenting symptoms. Results: Out of 463 newborns tested for cCMV, 21 (4.5%) were confirmed infected. The highest incidence of infection was identified among infants of mothers with suspected primary infection (8/42, 19%), followed by failed hearing screen (8/87, 9.2%), clinical suspicion alone (5/231, 2.2%), and HIV exposed (3/137, 2.2%). The most common symptoms present among those confirmed infected included microcephaly (9.4%), low birth weight (6.0%), thrombocytopenia (5.4%), intrauterine growth retardation (IUGR) (4.0%), and small for gestational age (SGA) (3.0%). Conclusions: These data suggest that microcephaly, thrombocytopenia, low birth weight, IUGR and HIV exposure in pregnancy should be additional criteria for enhanced targeted screening for cCMV, pending universal screening.
- To understand the limitations of current targeted screening approaches for the diagnosis of congenital CMV infection
- To describe the concept of an "enhanced" targeted screening approach
- To determine clinical criteria for a enhanced targeted screening approach
Presentation:
This presentation has not yet been uploaded.
Handouts:
Handout is not Available
Transcripts:
CART transcripts are NOT YET available, but will be posted shortly after the conference
Presenters/Authors
Fatima Kakkar
(), fatima.kakkar@umontreal.ca;
Dr Fatima Kakkar is a pediatric infectious diseases specialist and clinician-researcher in congenital infectious at Sainte-Justine University Health Center in Montreal, Canada, and Associate Professor of Pediatrics at the University of Montreal. Since 2017, she has co-directed the Women and Children’s Infectious Diseases Center “Centre d’infectiologie mère-enfant”, which provides care for infants affected by congenital infections in pregnancy. Her clinical and research
ASHA DISCLOSURE:
Financial -
Nonfinancial -